What to Expect From Medtronic's Q2 2026 Earnings Report

Core Insights - Medtronic plc (MDT) is a leading global healthcare technology company with a market cap of $120.1 billion, focusing on innovative solutions to improve health outcomes across more than 70 complex conditions [1] Financial Performance - Medtronic is expected to announce its fiscal Q2 2026 results on November 18, with analysts predicting an adjusted EPS of $1.31, a nearly 4% increase from $1.26 in the same quarter last year [2] - For fiscal 2026, analysts forecast an adjusted EPS of $5.62, reflecting a 2.4% rise from $5.49 in fiscal 2025, with further growth anticipated to $6.04 in fiscal 2027, representing a 7.5% year-over-year increase [3] Stock Performance - Over the past 52 weeks, Medtronic shares have increased by 3.1%, underperforming the S&P 500 Index, which rose nearly 18%, but outperforming the Health Care Select Sector SPDR Fund, which declined by 2.1% [4] Recent Results and Guidance - In Q1 2026, Medtronic reported an adjusted EPS of $1.26, exceeding consensus estimates and marking a 2.4% increase year-over-year. Revenue for the quarter was $8.58 billion, surpassing forecasts with an 8.3% year-over-year growth. The company raised its full-year adjusted EPS guidance to a range of $5.60 - $5.66 and projected organic revenue growth of 5% [5] Analyst Ratings - The consensus rating for MDT stock is "Moderate Buy," with 14 analysts recommending a "Strong Buy," one a "Moderate Buy," 15 a "Hold," and one a "Strong Sell." The average price target for Medtronic is $101.54, indicating a potential upside of 8.3% from current levels [6]